Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.60 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | MPO | P05164 | 4/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788064 | 1.00 | TAAR1 (0.60) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL4617147 | 0.86 | TAAR1 (0.56) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL1171657 | 0.84 | TAAR1 (0.54) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL29706272 | 0.84 | TAAR1 (0.71) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL1222973 | 0.84 | TAAR1 (0.71) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL16238934 | 0.82 | MGLL (0.56) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL9116334 | 0.82 | MGLL (0.56) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL1171532 | 0.82 | MGLL (0.56) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL29706378 | 0.81 | TAAR1 (0.68) | TAAR1HSPA5HTR1AMPOCYP2D6 | |
| SCHEMBL30600 | 0.81 | TDP1 (0.55) | TAAR1HSPA5HTR1ATSHRIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-109476683-B | Phenolic transition metal complexes, their production and use | 埃克森美孚化学专利公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113620821-A | Preparation method of hordenine hydrochloride | 广汉市派瑞林科技有限责任公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3490998-B1 | PHENOLATE TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3490998-B1 | PHENOLATE TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| CN-112041296-A | Aminoacetamides containing benzo-oxy-alicyclic structure and use thereof | 上海璃道医药科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | INHERIS BIOPHARMA INC (US) | 2020-03-12 | — | — | US | disclosed |
| CN-105503889-B | Oligomer-opioid agonist conjugates | 尼克塔治疗公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2019-08-15 | — | — | US | disclosed |
| EP-3490998-A1 | PHENOLATE TRANSITION METAL COMPLEXES, PRODUCTION AND USE THEREOF | ExxonMobil Chemical Patents Inc. (US) | 2019-06-05 | — | — | EP | disclosed |
| CN-101679254-A | The piperidines ketone that is used for inflammation treatment | BIOLIPOX AB | 2010-03-24 | — | — | CN | disclosed |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2010-02-25 | — | — | US | disclosed |
| CN-101522657-A | STAT3/5 activation inhibitor | OTSUKA PHARMA CO LTD (JP) | 2009-09-02 | — | — | CN | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| US-6100293-A | ANTIINFLAMMATORY AGENT EFFECTIVE IN THE PROPHYLAXIS OF ORGAN TRANSPLANT REJECTION; SIDE EFFECT REDUCTION | MERCK & CO., INC. (US) | 2000-08-08 | — | — | US | disclosed |
| US-6083980-A | 3B,7,9A-TRIMETHYL-1,3,3A,3B,4,5,5A,6,9,9A,9B,10,11,11A-TETRADE CAHYDRO PHENANTHRO(1,2-C)FURAN DERIVATIVE USED AS IMMUNOSUPPRESSANT TO PREVENT GRAFTING REJECTION | MERCK & CO., INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999020267-A1 | FURANYL, TETRACYCLIC TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| WO-1999020274-A1 | TETRACYCLIC TRITERPENE DERIVATIVES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0307106-A1 | P- or m-tert butoxyphenethyl alcohol and process for preparing the same | HOKKO CHEMICAL INDUSTRY CO., LTD (JP) | 1989-03-15 | — | — | EP | disclosed |
| EP-0087714-B1 | N-SUBSTITUTED (METH)-ACRYL AMIDE DERIVATIVES AND THEIR PREPARATION | BASF Aktiengesellschaft (DE) | 1984-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078353-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TAAR1 180/4885HSPA5 1527/4885HTR1A 221/4885 |
| US-20190247388-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | TAAR1 180/4885HSPA5 1527/4885HTR1A 221/4885 |
| US-20100048602-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | TAAR1 180/4885HSPA5 1527/4885HTR1A 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.